Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Neurology Immune Disorders Regulation

CHMP to review Tysabri as PML cases hit 23

This article was originally published in Scrip

Executive Summary

The CHMP is to review the "benefits and risks" of Elan/Biogen Idec's Tysabri (natalizumab) for the treatment of multiple sclerosis, based on an increasing rate of progressive multifocal leucoencephalopathy (PML). The CHMP reported that 23 cases of PML occurred worldwide since launch, higher than the 13 previously disclosed. Biogen Idec shares dropped by 7% on Nasdaq on October 23rd on the news, whereas Elan shares fell by around 17.5% on the NYSE.

Table

View full table

Topics

Related Companies

Tags:
Neurology Immune Disorders Regulation
Latest Headlines

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

See All
UsernamePublicRestriction

Register

SC005206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By